Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27574375 | 0.98 | CYSLTR1 (0.45) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL27539069 | 0.90 | PDE10A (0.44) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL7510557 | 0.83 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL27913232 | 0.79 | PDE10A (0.62) | PDE10ACYP1A2CYP2C9 | |
| SCHEMBL2913941 | 0.78 | PDE10A (0.61) | CYSLTR1CYSLTR2PDE10ACYP1A2CYP3A4 | |
| SCHEMBL2169411 | 0.77 | PDE10A (0.47) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL8764370 | 0.77 | CYSLTR1 (0.46) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL8800183 | 0.76 | CYSLTR1 (0.51) | CYSLTR1CYSLTR2PDE10AGPBAR1FFAR1 | |
| SCHEMBL10980763 | 0.75 | CYP1A2 (0.53) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL7131055 | 0.75 | PDE10A (0.44) | CYSLTR1CYSLTR2PDE10ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115825057-B | Application of quinoline carboxylic ester organic heterocyclic small molecule | 郑州轻工业大学 | 2023-08-22 | — | — | CN | claimed |
| CN-115825057-A | Application of quinoline carboxylic ester organic heterocyclic micromolecules | 郑州轻工业大学 | 2023-03-21 | — | — | CN | claimed |
| CN-115825057-B | Application of quinoline carboxylic ester organic heterocyclic small molecule | 郑州轻工业大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-115825057-A | Application of quinoline carboxylic ester organic heterocyclic micromolecules | 郑州轻工业大学 | 2023-03-21 | — | — | CN | disclosed |
| CN-110003121-A | A kind of 3,4- dihydroquinazoline derivatives and preparation method thereof, application | 郑州大学 | 2019-07-12 | — | — | CN | disclosed |
| CN-109762768-A | Bacillus B8W22 and its application | 浙江工业大学 | 2019-05-17 | — | — | CN | disclosed |
| CN-109689639-A | Spirolactams as ROCK inhibitor | 百时美施贵宝公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-105315308-A | Organic electroluminescent material and device | UNIVERSAL DISPLAY CORP | 2016-02-10 | — | — | CN | disclosed |
| CN-105163738-A | MK2 inhibitors and uses thereof | CELGENE AVILOMICS RES INC | 2015-12-16 | — | — | CN | disclosed |
| CN-103957910-A | Compounds and methods for enhancing innate immune responses | GLAXOSMITHKLINE LLC | 2014-07-30 | — | — | CN | disclosed |
| CN-101563318-A | N- (5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain | ABBOTT LAB (US) | 2009-10-21 | — | — | CN | disclosed |
| CN-100482672-C | novel 14 and 15 membered ring compounds | GLAXO GROUP LTD (GB) | 2009-04-29 | — | — | CN | disclosed |
| CN-101171254-A | Fused thieno[2,3-B]pyridine and thiazolo[5,4-B]pyridine compounds for inhibiting KSP kinesin activity | SCHERING CORP (US) | 2008-04-30 | — | — | CN | disclosed |
| CN-1332960-C | As adenosine A3Imidazoquinoline derivatives of receptor ligands | SANOFI AVENTIS (FR) | 2007-08-22 | — | — | CN | disclosed |
| CN-1852912-A | Novel 14 and 15 membered-ring compounds | GLAXO GROUP LTD (GB) | 2006-10-25 | — | — | CN | disclosed |
| CN-1849328-A | Novel 14 and 15 membered-ring compounds | GLAXO GROUP LTD (GB) | 2006-10-18 | — | — | CN | disclosed |
| CN-1726213-A | As adenosine A3Imidazoquinoline derivatives of receptor ligands | SANOFI AVENTIS (FR) | 2006-01-25 | — | — | CN | disclosed |
| EP-0726903-B1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX INC (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0726903-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX INC (US) | 1996-08-21 | — | — | EP | disclosed |
| WO-1995012603-A1 | MATRIX METALLOPROTEASE INHIBITORS________________________________ | SYNTEX (U.S.A.) INC. (US) | 1995-05-11 | — | — | WO | disclosed |